Share

September 2020; 7 (5) ArticleOpen Access

Long-term prognostic value of longitudinal measurements of blood neurofilament levels

Dieter A. Häring, Harald Kropshofer, Ludwig Kappos, Jeffrey A. Cohen, Anuja Shah, Rolf Meinert, David Leppert, Davorka Tomic, Jens Kuhle
First published August 12, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000856
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1033

Share

Article Information

vol. 7 no. 5 e856
DOI: 
https://doi.org/10.1212/NXI.0000000000000856
PubMed: 
32817406
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 30, 2020
  • Accepted in final form June 19, 2020
  • First Published August 12, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Dieter A. Häring, PhD,
    2. Harald Kropshofer, PhD,
    3. Ludwig Kappos, MD,
    4. Jeffrey A. Cohen, MD,
    5. Anuja Shah, PhD,
    6. Rolf Meinert, PhD,
    7. David Leppert, MD,
    8. Davorka Tomic, DVM, PhD and
    9. Jens Kuhle, MD, PhD
  1. Dieter A. Häring, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Novartis Pharma AG, Biostatistician, 12 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. As an employee of Novartis I receive stock as part of the contract

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Harald Kropshofer, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (19 Novartis Pharma AG, employee, 4 years.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ludwig Kappos, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Multiple Sclerosis and Related Disorders(2)Journal of Neurologymember of the Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Actelion, (2)Allmirall, (3)Bayer, (4) Baxalta,(5)Biogen, (6) CSL Behring,(7)Excemed, (8)Desitin,(9) Eisai,(10) Genzyme, (11) Japan Tobacco, (12)Merck,(13) Minoryx, (14)Novartis, (15)Pfizer,(16)Receptos/Celgene,(17)Roche,(18)sanofi-aventis,(19)Santhera,(20)Teva,

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)the Swiss MS Society, (2)the Swiss National ResearchFoundation, (3)the European Union, (4)Roche ResearchFoundations, (5) Innosuisse

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. (1) license fees for Neurostatus products paid directly toUniversity Hospital Basel

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jeffrey A. Cohen, MD,
    5. Scientific Advisory Boards:

    1. Adamas9/26/19 - ConsultingConvelo6/28/18, 7/31/18, 8/28/18, 10/2/18, 10/30/18, 11/28/18, 12/24/18, 1/29/19, 2/26/19, 3/26/19, 4/24/19, 5/22/19, 6/27/19, 7/24/19, 8/16/19 - ConsultingMedDay7/20/19 - ConsultingMylan9/19/19, 11/20/19 - ConsultingPopulation Council5/21/19 - Consulting

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Mylan10/5/18 - Speaker

    Editorial Boards:

    1. 2019-present - Editor, Multiple Sclerosis Journal, Sage

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Anuja Shah, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Novartis Healthcare Pvt. Ltd., Expert Scientific Writer, 2010 onwards

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Rolf Meinert, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. DATAMAP GmbH (Freiburg, Germany), Senior Biostatistician, since 2008

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. David Leppert, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel cost reimbursement and speaker honoraria from Sanofi, GeNeuro, Roche, Novartis and Orion

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. David Leppert has been a Novartis employee until January 2019. He is CMO of GeNeuro.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Novartisgranted 2019blocked until 2022

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Davorka Tomic, DVM, PhD and
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent on fingolimod's activity on T1 hypointense lesions (black holes)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Novartis Pharma AG; Global Brand Medical Director (Medical Affairs), July 2011-March 2020 - position is related to this manuscriptMerck KGaA; Senior Medical Director, from 15 April 2020 (position is not related to this manuscript)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. I am former employee of Novartis Pharma AG and hold stock in Novartis Pharma AG

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Jens Kuhle, MD, PhD
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer AG(2) Biogen(3) Celgene(4) Sanofi(5) Merck(4) Novartis(5) Roche

    Research Support, Government Entities:

    1. (1) Swiss National Research Foundation (320030_189140/1)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) ECTRIMS Research Fellowship Programme(2) University of Basel(3) Swiss MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Novartis Pharma AG (D.A.H., H.K., D.T.), Basel; Research Center for Clinical Neuroimmunology and Neuroscience Basel (L.K., D.L., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Switzerland; Department of Neurology (J.A.C.), Mellen MS Center, Neurological Institute, Cleveland Clinic, OH; Novartis Healthcare Pvt. Ltd. (A.S.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.
  1. Correspondence
    Dr. Kuhle Jens.Kuhle{at}usb.ch

Article usage

Article usage: August 2020 to October 2023

AbstractFullPdfSource
Aug 2020324292Highwire
Sep 2020125556168Highwire
Oct 2020735961Highwire
Nov 202069432Highwire
Dec 202064916Highwire
Jan 202176531Highwire
Feb 202185221Highwire
Mar 2021127324Highwire
Apr 202134721Highwire
May 202184420Highwire
Jun 202145416Highwire
Jul 202174119Highwire
Aug 202135310Highwire
Sep 202193116Highwire
Oct 202113424Highwire
Nov 202163736Highwire
Dec 202155225Highwire
Jan 202242714Highwire
Feb 202224722Highwire
Mar 202225824Highwire
Apr 202264228Highwire
May 202222823Highwire
Jun 202204419Highwire
Jul 202233219Highwire
Aug 202263312Highwire
Sep 202294518Highwire
Oct 2022186225Highwire
Nov 2022207329Highwire
Dec 2022183415Highwire
Jan 2023173517Highwire
Feb 2023143613Highwire
Mar 2023232816Highwire
Apr 2023203521Highwire
May 2023102815Highwire
Jun 2023202419Highwire
Jul 2023161915Highwire
Aug 2023162516Highwire
Sep 202311266Highwire
Oct 2023373515Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles